According to analysis on the basic characteristics of listed innovative drug, market access and medical insurance access from 2017 to 2020 in China, we provided a reference for the early layout of the follow-up market and medical insurance decision-making.
The chemical innovative drugs and biological drugs listed in China from 2017 to 2020 were selected as the research object, and the differences in drug types, production attributes and evaluation items were analyzed from the aspects of overall situation, disease field and medical insurance access.
The number of listed drugs increased steadily in the past four years. Among them, the number of chemical drugs was significantly higher than that of biological drugs, the number of imported drugs was significantly higher than that of domestic drugs, and the number of listed drugs, drugs entering the medical insurance catalogue and innovation review projects in the field of cancer were the largest.
In the future, chemical drugs will still occupy the dominant position in the market. Biopharmaceutical technology and domestic innovation ability need to be further improved. In popular areas such as oncology, drugs are more innovative and the access rate of drug medical insurance is also high.
| 科 Family | 属数 Number of genus | 种数 Number of species | 占总种数比例 Percentage of total species (%) | 属 Genus | 种数 Number of species | 占总种数比例 Percentage of total species (%) |
|---|---|---|---|---|---|---|
| 鹅膏菌科Amanitaceae | 2 | 11 | 5.26 | 鹅膏菌属 Amanita | 10 | 4.78 |
| 小菇科 Mycenaceae | 2 | 12 | 5.74 | 丝盖伞属 Inocybe | 5 | 2.39 |
| 多孔菌科 Polyporaceae | 8 | 14 | 6.70 | 蜡蘑属 Laccaria | 5 | 2.39 |
| 红菇科 Russulaceae | 3 | 23 | 11.00 | 小皮伞属 Marasmius | 6 | 2.87 |
| 小菇属 Mycena | 11 | 5.26 | ||||
| 光柄菇属 Pluteus | 5 | 2.39 | ||||
| 红菇属 Russula | 17 | 8.13 | ||||
| 栓菌属 Trametes | 5 | 2.39 |